Adaptin Bio (APTN) Cash & Equivalents (2022 - 2026)

Adaptin Bio has disclosed Cash & Equivalents across 5 years of filings, most recently posting $670488.0 for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 50.39% year-over-year to $670488.0; the TTM figure through Jun 2026 stood at $670488.0 (down 50.39% YoY), while the FY2025 annual figure was $459174.0, up 1247.14% from the prior year.
• Cash & Equivalents came in at $670488.0 for Q2 2026 at Adaptin Bio, up from $301309.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.4 million in Q1 2025 to a low of $322.0 in Q3 2024.
• Average Cash & Equivalents over 5 years is $446514.2, with a median of $34085.0 recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 179741.3% in 2025 and plunged 87.31% in 2026.
• Over 5 years, Cash & Equivalents stood at $500.0 in 2022, then soared by 850.8% to $4754.0 in 2023, then jumped by 616.98% to $34085.0 in 2024, then surged by 1247.14% to $459174.0 in 2025, then jumped by 46.02% to $670488.0 in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $670488.0 in Q2 2026, $301309.0 in Q1 2026, and $459174.0 in Q4 2025.